Jasper Therapeutics Q1 net loss $1.2M; refiles Phase 2b protocol for briquilimab in CSU

Jasper Therapeutics, Inc.

2026-Q1 EPS reported -$0.04

Cash and equivalents of $14.1M as of March 31, 2026, with $5.8M R&D and $5.1M G&A expenses.
Refiled Phase 2b protocol with FDA for briquilimab in chronic spontaneous urticaria; seeks funding to start H2 2026.
Jeet Mahal appointed CEO to lead next phase of clinical growth.
Positive clinical data: 67% of BEACON patients achieved complete response at 12 weeks; 75% in open-label achieved well-controlled disease.
Median follow-up >200 days; KIT-related AEs low-grade and resolved on study.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.